ArticleBritish journal of cancer2022

Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design.

Eske N Glud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.